The Trump administration despatched letters this summer time to 17 makers of name-brand medicine pushing them to decrease costs to align them with what different international locations pay. The businesses had 60 days to “step up.”
SCOTT DETROW, HOST:
Time is up for 17 drugmakers that obtained letters from the Trump administration this summer time. The letters gave the corporate 60 days to answer the administration’s calls for to decrease their costs. NPR prescription drugs correspondent Sydney Lupkin is right here to fill us in on what’s taking place. Hello, Sydney.
SYDNEY LUPKIN, BYLINE: Hello, Scott.
DETROW: So remind us, what does the administration need from these corporations?
LUPKIN: Yeah, the principle objective is to decrease the costs Individuals pay for name-brand medicine and put them in keeping with what different developed international locations pay, which is often loads much less. There was an government order pushing that concept in Could, however in August the Trump administration wasn’t glad with what it was listening to from the drug corporations, so it despatched letters to 17 of them with a listing of calls for – decrease costs in Medicaid, for instance. Launch new medicine at costs that match what individuals in different international locations are paying. Promote some medicine on to shoppers at decrease costs.
That stated, this could all be voluntary, however the letters carried a risk saying, quote, “when you refuse to step up, we’ll deploy each instrument in our arsenal to guard American households from continued abusive drug pricing practices.”
DETROW: So what have the businesses performed with this?
LUPKIN: So I reached out to all 17 corporations that obtained a letter. Most did not reply to me or declined to remark. Others touted adjustments in press releases, like Bristol Myers Squibb. It stated it’s going to provide its blood thinner Eliquis and a plaque psoriasis drug on to shoppers at a reduction. It additionally says it’s going to launch its new schizophrenia drug within the U.Okay. on the similar value it’s within the U.S., which, by the way in which, is nearly two grand a month. So no financial savings there for Individuals. However general, it does not sound just like the Trump administration obtained the pledges of widespread value reductions it hoped for. Juliette Cubanski is a Medicare drug pricing professional on the nonpartisan analysis group KFF.
JULIETTE CUBANSKI: This administration has a behavior of form of setting deadlines and blowing previous them with out something actually taking place.
LUPKIN: She says now that the deadline is right here, the administration might need to pivot to laws or rulemaking to get what it needs.
DETROW: So what’s our sense at this second about what this implies for shoppers?
LUPKIN: It’ll take a little bit longer to determine that out. The businesses should do some issues in response to the administration’s strain, and there are a couple of actions already, however they may not translate to decrease costs at U.S. pharmacy counters. For instance, after getting its letter in August, Eli Lilly stated that it could elevate the value of its Kind 2 diabetes drug Mounjaro within the U.Okay. And Lilly was clear in its announcement this was principally due to the Trump administration. However that does not essentially imply the value will go down right here within the U.S.
DETROW: Then how do tariffs match into all of this? As a result of that is been such a giant theme of this 12 months.
LUPKIN: The Trump administration is making an attempt every kind of issues on the similar time. It is pushing to get drug corporations to construct factories within the U.S. by tariffing some drug imports beginning subsequent month, and that might elevate costs. Steve Ubl, the CEO of the drug firm commerce group PhRMA, wrote that its members dedicated to spending 500 billion on infrastructure within the U.S. over the following few years. However it’s onerous to know the way the Trump administration’s actions will play out as a result of they’re taking place by way of government order and public strain. That is in contrast to laws that will get scored by the Congressional Price range Workplace. In that case, you possibly can see how a lot cash it’s going to value or save taxpayers, and we simply do not have that right here.
DETROW: Bought it. That’s NPR prescription drugs correspondent Sydney Lupkin. Thanks a lot.
LUPKIN: You guess.
(SOUNDBITE OF BADBADNOTGOOD AND GHOSTFACE KILLAH SONG, “FOOD”)
Copyright © 2025 NPR. All rights reserved. Go to our web site phrases of use and permissions pages at www.npr.org for additional info.
Accuracy and availability of NPR transcripts might fluctuate. Transcript textual content could also be revised to right errors or match updates to audio. Audio on npr.org could also be edited after its unique broadcast or publication. The authoritative document of NPR’s programming is the audio document.
